NPXe is seeking international distribution partners in select ROW countries to help us achieve our mission. We have completed the preclinical studies necessary for the filing of an IND (US) and RMS & CMS (EU). We own exclusive worldwide, royalty-free rights to Xenon + XENEX™ therapy.
XENEX™ is an inhaled gas that has shown promising potential as a neuroprotectant when administrated to a patient after a cardiac arrest, in combination with hypothermia/targeted temperature management [TH/TTM] therapy.
Phase II Superiority Study, published in JAMA in March 2016, showed statistically significantly less white matter damage and directionally positive survival outcomes between a xenon plus TTM group versus a TTM alone group. Overall the study showed:
- Less white matter damage
- Trend towards better survival outcomes
- Excellent safety profile
Contact: All partnering inquiries should be directed to email@example.com